3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
4
Colorectal Neoplasms
3
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Solid Tumors
1
Rectal Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Brain Neoplasms
1
Advanced Solid Tumor
1
Interventions
Capecitabine
22
Oxaliplatin
19
Fluorouracil
16
Radiotherapy
11
Leucovorin
10
Cetuximab
9
Nivolumab
7
Bevacizumab
6
sintilimab
5
Specimen Handling
5
Radiotherapy, Intensity-Modulated
5
Magnetic Resonance Spectroscopy
5
Irinotecan
5
Folfox protocol
5
trifluridine tipiracil drug combination
4
pembrolizumab
4
Surgical Procedures, Operative
4
encorafenib
3
X-Rays
3
Trastuzumab
3
Surveys and Questionnaires
3
Sigmoidoscopy
3
Radiation
3
Pemetrexed
3
Gemcitabine
3
Endoscopy
3
Control Groups
3
Consolidation Chemotherapy
3
Cisplatin
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
adagrasib
×
90 days
×
Clear all
NCT04793958
2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3
Active not recruiting
461 enrolled